Top Page
Evaxion Biotech
(NASDAQ:EVAX)
Evaxion Biotech (EVAX) vs. SPDR S&P 500 ETF (SPY)
Evaxion Biotech Business Overview & Revenue Model
Evaxion Biotech Earnings Call Summary
Evaxion Biotech Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.65M | 3.34M | 73.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.65M | 3.34M | 73.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -5.96M | -9.79M | -21.40M | -22.57M | -24.21M | -16.46M |
| Net Income | -5.42M | -10.57M | -22.13M | -23.17M | -24.53M | -15.02M |
Balance Sheet | ||||||
| Total Assets | 29.74M | 12.48M | 12.89M | 22.02M | 40.16M | 11.96M |
| Cash, Cash Equivalents and Short-Term Investments | 10.57M | 5.05M | 4.18M | 13.18M | 32.17M | 5.83M |
| Total Debt | 0.00 | 10.10M | 10.87M | 10.26M | 3.69M | 20.00K |
| Total Liabilities | 13.14M | 14.14M | 17.62M | 13.72M | 7.73M | 4.93M |
| Stockholders Equity | 16.60M | -1.65M | -4.73M | 8.30M | 32.44M | 7.04M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -12.94M | -17.78M | -26.07M | -23.29M | -12.83M |
| Operating Cash Flow | 0.00 | -12.94M | -17.69M | -25.77M | -21.93M | -12.44M |
| Investing Cash Flow | 0.00 | -3.00K | -93.00K | -268.00K | -1.33M | -393.00K |
| Financing Cash Flow | 0.00 | 13.13M | 10.69M | 7.85M | 49.80M | 8.82M |
Evaxion Biotech Technical Analysis
Evaxion Biotech Risk Analysis
Evaxion Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $30.26M | -0.49 | ― | ― | 4455.07% | 77.31% | |
56 Neutral | $121.68M | -2.11 | ― | ― | 234.73% | 81.16% | |
54 Neutral | $44.30M | -1.04 | ― | ― | ― | 49.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $34.78M | -0.89 | ― | ― | -14.92% | 72.81% | |
48 Neutral | $49.00M | -4.47 | -3071.15% | ― | 36.89% | 43.58% | |
47 Neutral | $27.82M | -3.80 | -83.34% | ― | -6.51% | 58.31% |
Evaxion Biotech Corporate Events
On January 13, 2026, Evaxion A/S announced that it is expanding its AI-Immunology platform into autoimmune diseases, adding this as a third core therapeutic area alongside cancer and infectious diseases. The move is intended to leverage the scalability of its AI technology to generate a broader and higher-quality pipeline of precision treatments that address underlying disease mechanisms rather than just symptoms, thereby enhancing the company’s partnership potential across all stages of drug development. Evaxion stated that the training of AI-Immunology for autoimmune applications is planned for the second half of 2026 and that this work is already incorporated into its financial plans, with its cash runway still expected to extend into the second half of 2027. The company also outlined key 2026 milestones, including additional biomarker and immunogenicity data and three-year Phase 2 efficacy data for EVX-01, a regulatory filing for a Phase 1 trial of EVX-04, a preclinical antigen design milestone for EVX-B4, and the launch of the new autoimmune application, underscoring continued execution of its strategy to create value from both its platform and pipeline assets through partnerships.
The most recent analyst rating on (EVAX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On January 7, 2026, Evaxion A/S announced that it will present its 2026 company milestones and provide a corporate update at the Biotech Showcase conference in San Francisco, held January 12-14, 2026. Chief executive Helen Tayton-Martin is scheduled to speak on January 13, 2026, with Evaxion also planning broader engagement with potential business partners and other stakeholders during the week, coinciding with the high-profile J.P. Morgan Healthcare Conference, which could enhance the company’s visibility and partnering prospects in the biotech and life sciences investment community.
The most recent analyst rating on (EVAX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On December 19, 2025, Evaxion A/S reported that its collaboration partner MSD chose not to exercise an option to develop Evaxion’s gonorrhea vaccine candidate EVX-B2, leaving Evaxion with global rights and the ability to seek a new licensing partner for the asset. The company emphasized that preclinical data show EVX-B2 protects against gonorrhea, a disease affecting more than 80 million people annually with no approved vaccine, and noted that MSD’s decision does not affect Evaxion’s cash runway, which it says still extends into the second half of 2027; Evaxion also continues its separate mRNA-based EVX-B2 program with Afrigen Biologics and retains potential milestone and royalty upside from MSD’s earlier exercise of an option on a different vaccine candidate, EVX-B3.
The most recent analyst rating on (EVAX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On December 10, 2025, Evaxion Biotech A/S filed a prospectus supplement with the SEC for the offer and sale of American Depositary Shares (ADSs), each representing fifty ordinary shares, with an aggregate offering price of up to $45,527,824. This filing is part of their Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, and it updates previous prospectuses to facilitate the sale of ADSs. This strategic financial move aims to bolster Evaxion’s capital, potentially enhancing its market position and operational capabilities in the biotechnology sector.
The most recent analyst rating on (EVAX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On December 6, 2025, Evaxion A/S presented new data at the ASH Annual Meeting demonstrating the efficacy of their cancer vaccine candidate, EVX-04, for acute myeloid leukemia (AML). The vaccine, developed using Evaxion’s AI-Immunology™ platform, targets non-conventional ERV tumor antigens and has shown promising results in preclinical models by inducing targeted immune responses and preventing tumor growth. This development could significantly improve treatment options for AML, a disease with high mortality rates and limited current therapies, and highlights the potential of AI-Immunology™ in creating transformative cancer treatments.
The most recent analyst rating on (EVAX) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On November 20, 2025, Evaxion A/S announced positive data from its cytomegalovirus (CMV) vaccine program, EVX-V1. The program, which leverages Evaxion’s AI-Immunology™ platform, has identified novel antigens that significantly reduce viral infection in preclinical models. This advancement is crucial as no CMV vaccine has been approved despite decades of research, highlighting the importance of these findings. The company continues to optimize and investigate these AI-derived antigens while exploring strategic partnerships to advance the vaccine into clinical phases.
The most recent analyst rating on (EVAX) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On November 4, 2025, Evaxion Biotech announced a share capital increase following the exercise of certain investor warrants. This resulted in the issuance of 1,875,000 ordinary shares, raising the company’s share capital to nominal DKK 104,252,689. The capital increase, registered with the Danish Business Authority, reflects a cash consideration of USD 101,625. This move is part of Evaxion’s strategic efforts to strengthen its financial position and potentially enhance its market presence.
The most recent analyst rating on (EVAX) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On November 12, 2025, Evaxion A/S announced its financial calendar for 2026, detailing key dates for business updates and financial results throughout the year. This announcement is significant for stakeholders as it outlines the company’s timeline for financial disclosures and strategic updates, which are crucial for investors and market analysts to track the company’s progress and financial health.
The most recent analyst rating on (EVAX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On November 7, 2025, Evaxion A/S announced new immune data from its phase 2 trial of the AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The data, which builds on previous clinical efficacy results, highlights the vaccine’s ability to induce specific immune responses in patients with advanced melanoma when used in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®. This development further strengthens EVX-01’s data package and underscores its potential impact on cancer treatment, drawing significant interest from the medical community.
The most recent analyst rating on (EVAX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On November 6, 2025, Evaxion A/S announced significant business developments and financial results for the third quarter of 2025. Key highlights include the appointment of Dr. Helen Tayton-Martin as the new CEO, effective November 24, 2025, and the presentation of promising phase 2 trial data for their personalized cancer vaccine, EVX-01, at the ESMO Congress. The company also reported the out-licensing of their bacterial vaccine candidate, EVX-B3, to MSD, which has extended their cash runway to the second half of 2027. These developments underscore Evaxion’s strategic focus on leveraging its AI-Immunology™ platform for vaccine innovation and expanding its market presence through strategic partnerships.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On November 3, 2025, Evaxion A/S announced the expansion of its R&D pipeline with the introduction of EVX-04, a new AI-designed precision cancer vaccine candidate. EVX-04 targets non-conventional ERV tumor antigens and is designed as a therapeutic vaccine for acute myeloid leukemia. The vaccine, which induces strong T-cell responses, will be presented at the American Society of Hematology Annual Meeting in December, highlighting its potential to improve outcomes for patients who do not respond to conventional immunotherapies.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On October 31, 2025, Evaxion A/S announced it will provide a business update and report its third quarter 2025 financial results on November 6, 2025. The company will host a conference call and webcast to present the update and results, which will be open to the public. This announcement is part of Evaxion’s ongoing efforts to engage with stakeholders and provide transparency about its financial health and strategic direction.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Evaxion Biotech A/S announced amendments to its Articles of Association following the exercise of certain investor warrants, resulting in an increase in share capital. From October 15 to October 28, 2025, the company registered a total share capital increase of nominal DKK 4,735,475, raising the total share capital to DKK 103,783,939. This move, which involved the issuance of multiple ordinary shares over several days, reflects the company’s ongoing efforts to enhance its financial standing and operational capacity, potentially impacting its market position and shareholder value.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On October 30, 2025, Evaxion A/S announced it raised $7.2 million, extending its cash runway to the second half of 2027. This financial boost comes from the sale of shares and the exercise of warrants, strengthening Evaxion’s cash position and equity. The company has also reduced its outstanding warrants by 1.0 million, enhancing its financial stability. This development follows a $7.5 million payment from MSD for licensing a vaccine candidate in September 2025, further supporting Evaxion’s strategic focus on executing its R&D programs and operations.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On October 27, 2025, Evaxion A/S announced the appointment of Dr. Helen Tayton-Martin as the new Chief Executive Officer, effective November 24, 2025. Dr. Tayton-Martin, with over 30 years of experience in biotech, including leadership roles in cancer immunotherapy, is expected to lead Evaxion’s strategic execution. Her appointment is seen as a significant step for the company, which is well-positioned for future growth with its AI-Immunology platform and recent strategic partnerships. Additionally, Jens Bitsch-Norhave will join the Board of Directors as an advisor, bringing extensive experience in corporate strategy and global expansion.
The most recent analyst rating on (EVAX) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On September 25, 2025, Evaxion Biotech A/S sold 1,018,000 American Depositary Shares (ADSs) in an at-the-market offering, generating approximately $4.3 million in proceeds. The company’s share capital increased significantly, with amendments to the Articles of Association reflecting these changes. Between October 3 and October 10, 2025, further share capital increases occurred due to the exercise of investor warrants, raising additional funds and expanding the company’s capital base. These financial activities are part of Evaxion’s strategic efforts to bolster its market position and operational capabilities.
The most recent analyst rating on (EVAX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
On October 17, 2025, Evaxion Biotech announced impressive results from a phase 2 trial of its AI-designed personalized cancer vaccine, EVX-01, for advanced melanoma. The trial demonstrated a 75% Objective Response Rate, with 12 out of 16 patients showing clinical responses, and 92% of patients still responding after 24 months. The data, presented at the ESMO Congress, highlights the vaccine’s potential as a new treatment option and underscores the precision of Evaxion’s AI-Immunology platform in identifying neoantigens. The company plans further clinical development in partnership, marking a significant milestone in personalized immunotherapy.
The most recent analyst rating on (EVAX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.